0001415889-25-024463.txt : 20250912 0001415889-25-024463.hdr.sgml : 20250912 20250912200009 ACCESSION NUMBER: 0001415889-25-024463 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250911 FILED AS OF DATE: 20250912 DATE AS OF CHANGE: 20250912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brege Laura CENTRAL INDEX KEY: 0001365619 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38981 FILM NUMBER: 251312879 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001759425 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 831281555 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 989 EAST HILLSDALE BOULEVARD, SUITE 300 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-667-4085 MAIL ADDRESS: STREET 1: 989 EAST HILLSDALE BOULEVARD, SUITE 300 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 form4-09122025_080904.xml X0508 4 2025-09-11 0001759425 Mirum Pharmaceuticals, Inc. MIRM 0001365619 Brege Laura C/O MIRUM PHARMACEUTICALS, INC. 989 E HILLSDALE BLVD., SUITE 300 FOSTER CITY CA 94404 true false false false 0 Common Stock 2025-09-11 4 M 0 17000 15 A 32703 D Common Stock 2025-09-11 4 S 0 15509 74.34 D 17194 D Common Stock 2025-09-11 4 S 0 1491 75.07 D 15703 D Stock Option (right to buy) 15 2025-09-11 4 M 0 17000 0 D 2029-07-16 Common Stock 17000 0 D The weighted average sale price for the transaction reported was $74.34, and the range of prices were between $73.73 and $74.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $75.07, and the range of prices were between $74.745 and $75.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The stock option is fully vested. /s/ Judit Ryvkin, Attorney-in-Fact 2025-09-12